New drugs for HDL-C disorders: The beginning

My Ngan Duong; Stephen J. Nicholls

doi:10.2174/0929867321666140414104130

New drugs for HDL-C disorders: The beginning

My Ngan Duong, Stephen J. Nicholls

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed.

Original language	English
Pages (from-to)	2947-2951
Number of pages	5
Journal	Current Medicinal Chemistry
Volume	21
Issue number	25
DOIs	https://doi.org/10.2174/0929867321666140414104130
Publication status	Published or Issued - Aug 2014

Keywords

Atherosclerosis
Cardiovascular disease
HDL
Lipids
Risk factors

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Pharmacology
Drug Discovery
Organic Chemistry

Access to Document

10.2174/0929867321666140414104130

Cite this

@article{4ee1cd913d87426cbed3669d750b0749,

title = "New drugs for HDL-C disorders: The beginning",

abstract = "For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed.",

keywords = "Atherosclerosis, Cardiovascular disease, HDL, Lipids, Risk factors",

author = "Duong, {My Ngan} and Nicholls, {Stephen J.}",

year = "2014",

month = aug,

doi = "10.2174/0929867321666140414104130",

language = "English",

volume = "21",

pages = "2947--2951",

journal = "Current Medicinal Chemistry",

issn = "0929-8673",

publisher = "Bentham Science Publishers B.V.",

number = "25",

}

TY - JOUR

T1 - New drugs for HDL-C disorders

T2 - The beginning

AU - Duong, My Ngan

AU - Nicholls, Stephen J.

PY - 2014/8

Y1 - 2014/8

N2 - For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed.

AB - For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed.

KW - Atherosclerosis

KW - Cardiovascular disease

KW - HDL

KW - Lipids

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84906095401&partnerID=8YFLogxK

U2 - 10.2174/0929867321666140414104130

DO - 10.2174/0929867321666140414104130

M3 - Article

C2 - 24735360

AN - SCOPUS:84906095401

VL - 21

SP - 2947

EP - 2951

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 25

ER -

New drugs for HDL-C disorders: The beginning

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this